Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                MCM Issues

MCM Issues

                        Advanced Manufacturing
          Antimicrobial Resistance Information from FDA
          Ebola Preparedness and Response Updates from FDA
          FDA/DoD Collaborations
          FDA Mpox Response
          Medical Countermeasure Monitoring and Assessment
          Pediatric Medical Countermeasures
          Preparedness Information for Consumers
          Radiological and Nuclear Emergency Preparedness Information from FDA
          Smallpox Preparedness and Response Updates from FDA
          Zika Virus Response Updates from FDA Home
          Emergency Preparedness and Response
          Counterterrorism and Emerging Threats
          Medical Countermeasures Initiative (MCMi)
          MCM Issues
          FDA/DoD CollaborationsMCM Issues FDA/DoD Collaborations
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              Combat medics conduct an exercise at the Marine Corps Training Area Bellows, Hawaii, on Jan. 10, 2018. (U.S. Army photo by Staff Sgt. Armando R. Limon, 3rd Brigade Combat Team, 25th Infantry Division)Enhanced Engagements for Products Relevant to the Department of Defense (DoD)

Public Law 115-92, enacted December 12, 2017, authorized the Department of Defense (DoD) to request, and the U.S. Food and Drug Administration (FDA) to provide, assistance to expedite development and the FDA’s review of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel. On January 16, 2018, the FDA and DoD announced the launch of a joint program to prioritize the efficient development of safe and effective medical products intended for deployed American military personnel.

Utilizing these expanded authorities, the FDA works closely with DoD’s Office of Health Affairsto better understand the military’s medical needs for deployed personnel; give the highest level of attention to and expedite its review of priority DoD medical products in a manner similar to products under the breakthrough therapy designation; provide ongoing technical advice to DoD to aid in the rapid development and manufacturing of medical products for use by the military; and, take a closer look at products currently under development to determine opportunities to expedite their availability.

On November 2, 2018, FDA and DoD signed a Memorandum of Understanding (MOU) setting forth the framework for the ongoing partnership and the creation of a robust program that can better serve the health care needs of American military personnel.

Additional details

**Public Law (PL) 115-92** - information from DoD
	**Initial Work Plan for Products Relevant to the Department of Defense** (PDF, 115 KB) (January 16, 2018)
	**News release:**FDA and DoD launch program to expedite availability of medical products for the emergency care of American military personnel (January 16, 2018)
	**News release:** FDA and DoD formalize collaboration to advance medical products in support of American military personnel(November 2, 2018)
	MOU Concerning Coordination with FDA Regarding DoD Medical Product Development and Assessment(MOU 225-19-01) (November 2, 2018)

Related links

March 2, 2023: FDA cleared a commercially available laboratory traumatic brain injury (TBI) blood test, which will provide clinicians with an objective way to quickly assess individuals with mild TBIs, also known as concussions. Abbott's Alinity i TBI lab test offers results in 18 minutes, as compared to the previously approved Banyan BTI test which takes 4 hours, to help health care providers quickly assess concussion and triage patients. For those with negative results, it rules out the need for a CT scan. The test measures two biomarkers in the blood that, in elevated concentrations, are tightly correlated to brain injury. The DoD, through U.S. Army Medical Research and Development Command's (USAMRDC) U.S. Army Medical Materiel Development Activity (USAMMDA), played a critical role in developing this test run on Abbott's i-STAT Alinity platform. Previously, in January 2021, the DoD announced FDA clearance of a field-deployable rapid, handheld TBI blood test, thei-STAT TBI Plasma cartridge, which runs on the same platform.
	August 8, 2022: FDA approved a New Drug Application (NDA) for the use of Midazolam Injection, 10 mg/0.7 mL, autoinjector, for the treatment of status epilepticus in adults. DoD developed the product with Rafa Laboratories, Ltd. According to JPEO-CBRND (the U.S. Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense), the autoinjector "improves upon and will replace the currently fielded convulsant antidote for nerve agent (CANA) diazepam autoinjector."  For more information, see the NDA approval letter (PDF, 302 KB) and product label (PDF, 913 KB).
	February 28, 2022: FDA approved a New Drug Application (NDA) for a naloxone hydrochloride autoinjector for use by military personnel and chemical incident responders for emergency treatment of patients 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon is suspected, and for temporary prophylaxis of respiratory and/or central nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids such as fentanyl analogues. For more information, see the NDA approval letter (PDF, 155 KB) and product label (PDF, 697 KB).
	August 13, 2021: FDA approved a Biologics License Application for TICOVAC (Tick-Borne Encephalitis Vaccine), for active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older. The vaccine is manufactured by Pfizer Ireland Pharmaceuticals; development of this vaccine has been an important need for the U.S. military.
	December 20, 2019: Department of the Army, the Surgeon General-Sponsored Assay Supports First-Ever FDA-Approved Ebola Vaccine in U.S. (DoD news release)
	December 19, 2019: FDA finalized the guidance Considerations for the Development of Dried Plasma Products Intended for Transfusion. This guidance provides recommendations for the development of safe and effective dried plasma products intended for transfusion; it finalizes the guidance of the same title dated October 2018.
	August 29, 2019: FDA Action Makes Blood Product More Accessible to Warfighters in Combat (DoD news release)
	November 2, 2018: Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s approval of Dsuvia and the FDA’s future consideration of new opioids
	October 29, 2018: FDA issues draft guidance on the development of dried plasma products intended for transfusion
	September 14, 2018: DoD and FDA collaborate to help speed potential countermeasures for Ebola and other viruses
	August 10, 2018: Breakthrough in Malaria Prevention: U.S. Army Medical Materiel Development Activity (USAMMDA) Announces FDA Approval of New Antimalarial Drug(DoD news release)
	July 10, 2018: FDA takes action to support American military personnel by granting an authorization for freeze-dried plasma product to enable broader access while the agency works toward approval of the product
	February 14, 2018:FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults
	MCM-Related Counterterrorism Legislation
	MCMi Collaborations

                                                                                  Content current as of:
      03/29/2023
              
              
Topic(s)
			  PartnershipsMCM Issues

          
                        Advanced Manufacturing
          Antimicrobial Resistance Information from FDA
          Ebola Preparedness and Response Updates from FDA
          FDA/DoD Collaborations
          FDA Mpox Response
          Medical Countermeasure Monitoring and Assessment
          Pediatric Medical Countermeasures
          Preparedness Information for Consumers
          Radiological and Nuclear Emergency Preparedness Information from FDA
          Smallpox Preparedness and Response Updates from FDA
          Zika Virus Response Updates from FDA
 Subscribe
                        Sign up to receive email alerts on emergency preparedness and response topics from FDA, including medical countermeasures and emerging infectious diseases.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop